PHIBRO ANIMAL HEALTH CORP
PAHC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PAHC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PAHC
Phibro Animal Health Corp. is a diversified animal health and nutrition company that develops, manufactures, and markets products for livestock and companion animals, with a focus on medicated feed additives, vaccines, and nutritional specialties.
Key risk: High debt leverage
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$1.53B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Phibro Animal Health Corp. is a diversified animal health and nutrition company that develops, manufactures, and markets products for livestock and companion animals, with a focus on medicated feed additives, vaccines, and nutritional specialties.
- Phibro's product portfolio includes medicated feed additives, vaccines, and nutritional specialties for food-producing and companion animals [sec_mda · as of 2026-08-26].
- The company faces risks from outbreaks of animal diseases, which could reduce demand for its products or availability of raw materials [sec · filed 2026-05-06].
- Phibro's future success depends on its existing product portfolio and its ability to obtain approvals for new uses, species, claims, and markets, as well as its pipeline of new products [sec_mda · as of 2026-08-26].
- As of June 30, 2026, Phibro reported cash & equivalents of $61.4M, shareholders' equity of $285.7M, and total debt of $737.9M [sec].
- The company is subject to risks from restrictions on the use of antibacterials in food-producing animals and from perceived adverse effects on human health linked to animal products [sec · filed 2026-05-06].
What works
- Phibro has a diversified product portfolio spanning medicated feed additives, vaccines, and nutritional specialties, which may provide multiple revenue streams [sec_mda · as of 2026-08-26].
- The company's strategic initiatives include product approval, R&D, acquisition, and licensing efforts to generate new products and lifecycle developments [sec_mda · as of 2026-08-26].
- Phibro's long-term presence in the animal health industry suggests established relationships and manufacturing capabilities [sec · filed 2026-05-06].
What to weigh
- Phibro carries a high debt load of $737.9M as of June 30, 2026, which may constrain financial flexibility [sec].
- The company is exposed to regulatory risks, including potential restrictions on antibacterials in food-producing animals, which could impact product sales [sec · filed 2026-05-06].
- Outbreaks of animal diseases could significantly reduce demand for Phibro's products or disrupt raw material supply [sec · filed 2026-05-06].
- Phibro's R&D and product approval efforts may fail to generate new products, limiting future growth [sec_mda · as of 2026-08-26].
From the filings
Quoted directly from source documents.
Phibro's future success depends on its existing product portfolio and pipeline of new products.
“Our future success depends on both our existing product portfolio, including our ability to obtain cross-clearances enabling the use of our medicated products in conjunction with other products, approval for use of our products with new species, approval for new claims for our products, approval of our products in new markets and our pipeline of new products, including new products that we may develop through joint ventures and products that we are able to obtain through license or acquisit”
SEC MD&A · August 26, 2026
Outbreaks of animal diseases are a key risk.
“outbreaks of animal diseases could significantly reduce demand for our products or availability of raw materials”
SEC filings · May 6, 2026
Restrictions on antibacterials in food-producing animals are a risk.
“restrictions on the use of antibacterials in food-producing animals may become more p”
SEC filings · May 6, 2026
Risks & what to watch (4)›
Key risks
- High debt leverage — Total debt of $737.9M as of June 30, 2026, against shareholders' equity of $285.7M, indicating significant leverage [sec].
- Regulatory restrictions on antibacterials — Potential restrictions on the use of antibacterials in food-producing animals could reduce demand for key products [sec · filed 2026-05-06].
- Animal disease outbreaks — Outbreaks could reduce product demand and raw material availability, impacting operations [sec · filed 2026-05-06].
- R&D and product approval failure — Failure of product approval, R&D, acquisition, and licensing efforts to generate new products could limit growth [sec_mda · as of 2026-08-26].
What to watch
- Monitor Phibro's ability to manage its high debt load and interest obligations [sec].
- Track regulatory developments regarding antibacterial use in livestock, which could affect product sales [sec · filed 2026-05-06].
- Watch for updates on product approvals, new claims, or market expansions that could drive revenue growth [sec_mda · as of 2026-08-26].
- Observe any impact from animal disease outbreaks on demand and supply chains [sec · filed 2026-05-06].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run PHIBRO ANIMAL HEALTH CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PHIBRO ANIMAL HEALTH CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 2.89
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
1 buy · 45 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
258
Total value held
$1.07B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 3,253,848 | $180.0M |
| fmr llc | 2,173,126 | $120.2M |
| vanguard capital management llc | 1,782,566 | $98.6M |
| state street corp | 950,033 | $52.5M |
| geode capital management, llc | 604,648 | $33.4M |
| renaissance technologies llc | 576,735 | $31.9M |
| dimensional fund advisors lp | 507,852 | $28.1M |
| vanguard portfolio management llc | 490,342 | $27.1M |
| morgan stanley | 391,187 | $21.6M |
| invesco ltd. | 330,977 | $18.3M |
Showing top 10 of 258 institutional holders of PHIBRO ANIMAL HEALTH CORP. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 6.9%
- Days to cover
- 4.6
- Shares short
- 1,215,037
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PAHC short interestGovernance
Frequently asked questions
What is the AI investment thesis for PHIBRO ANIMAL HEALTH CORP?
Phibro Animal Health Corp. is a diversified animal health and nutrition company that develops, manufactures, and markets products for livestock and companion animals, with a focus on medicated feed additives, vaccines, and nutritional specialties.
Who is the CEO of PHIBRO ANIMAL HEALTH CORP?
Mr. Daniel M. Bendheim J.D. is the chief executive officer of PHIBRO ANIMAL HEALTH CORP (PAHC).
Where is PHIBRO ANIMAL HEALTH CORP headquartered?
PHIBRO ANIMAL HEALTH CORP (PAHC) is headquartered in Teaneck, NJ, United States.
What therapeutic areas does PHIBRO ANIMAL HEALTH CORP focus on?
PHIBRO ANIMAL HEALTH CORP develops therapies across Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.